Cargando…
Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo
Development of engineered non-pathogenic bacteria, capable of expressing anti-cancer proteins under tumor-specific conditions, is an ideal approach for selectively eradicating proliferating cancer cells. Herein, using an engineered hypoxia responding nirB promoter, we developed an engineered Escheri...
Autores principales: | Samadi, Mitra, Majidzadeh-A, Keivan, Salehi, Malihe, Jalili, Neda, Noorinejad, Zeinab, Mosayebzadeh, Marjan, Muhammadnejad, Ahad, Sharif khatibi, Azadeh, Moradi-Kalbolandi, Shima, Farahmand, Leila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330025/ https://www.ncbi.nlm.nih.gov/pubmed/34344421 http://dx.doi.org/10.1186/s13036-021-00269-2 |
Ejemplares similares
-
Correction: Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo
por: Samadi, Mitra, et al.
Publicado: (2022) -
Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors
por: Merikhian, Parnaz, et al.
Publicado: (2021) -
The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development
por: Moradi-kalbolandi, Shima, et al.
Publicado: (2021) -
Potential role of interferons in treating COVID-19 patients
por: Haji Abdolvahab, Mohadeseh, et al.
Publicado: (2021) -
AKAP3 correlates with triple negative status and disease free survival in breast cancer
por: Esmaeili, Rezvan, et al.
Publicado: (2015)